MAPT and tauopathy: In fact, in tauopathies, little is reported about whether SU drugs play a role in the pathological aggregation of tau protein or can act as a neuroprotective agent against tauopathy but many reports supported that SU drugs can implicate in amelioration of number of acute pathological conditions involving the CNS (Hussien et al. 2018).Glibenclamide as a prototype SU drug was reported to reduce brain edema induced by neuronal injury (Delpire et al. 2009), and ameliorate spinal cord injury and cerebral stroke by anti-inflammatory effects and activation of neurogenesis (Tosun et al. 2013).